Granada and Madrid, Spain and Madison, WI, U.S., February 26, 2014 – Integromics®, a market leader in IT solutions for life sciences in the field of genomics and proteomics, today announces that it has released Version 5.0 RealTime StatMiner® software for qPCR gene expression workflows. “Our customers have been asking for enhanced processivity of large data files and advanced statistical analysis of complex experimental results”, says Victor Canivell, CEO, Integromics. “Given the high throughput requirements of many-RT-qPCR projects, our enriched version of RealTime StatMiner software has been developed to fulfill the needs of our customers.”
With an increased number of plates in high throughput applications, Version 5.0 addresses the new challenges for qPCR data analysis by including an improved data loader to easily handle large data files from a variety of instrument platforms and a new method for normalization of data across multiple plates. In this way Version 5.0 enhances the reliability of qPCR data analysis from experiments that may have been performed at different times and locations
With the new interactive Principal Component Analysis (PCA) tool, now it is possible to identify outliers and clusters of genes or samples with similar expression patterns within datasets that are becoming increasingly larger and more complex.
Version 5.0 also provides new features for reporting of RT-qPCR analysis results, such as the automatic generation of gene lists showing altered expression between conditions and multiple comparison visualizations.
With this release, RealTime StatMiner steps into the era of single-cell transcriptomics by incorporating a new workflow for single-cell qPCR data analysis. “Single-cell analysis is becoming more popular in research both in industry and academia, and the new version of RealTime StatMiner allows Integromics to position itself as a competitive player in this field”, says David Gonzalez, product manager, Integromics.
The new version of RealTime StatMiner software is available for immediate release. More information here.
Integromics develops and markets advanced data analysis solutions for life sciences in the areas of genomics and proteomics. Integromics offers state-of-the-art products, services and training for intelligent, visual analysis and integration of biological data. Its international network of collaborators in industry and academia helps researchers to achieve faster and more complete biological interpretations of experimental omics data. Integromics was founded in 2002 in Granada, Spain, with offices in Madrid, Spain and Wisconsin, USA. Additional information is available at http://www.integromics.com.]]>
On February 2, 2012 it was announced that Integromics®, a market leader in IT solutions provision for life sciences in the field of genomics and proteomics, entered into a partnership with Professor Carracedo and his team at the Galician Foundation of Genomic Medicine (FPGMX), a recipient of the European Life Technologies ‘Ion Torrent Visionary Winners Award’, for the development of inexpensive solutions for clinical genomics.
This collaboration is framed in the R&D project entitled ‘Advanced analysis and interpretation of Low-cost next generation sequencing data for clinical applications’ (ApliClinics), which is being funded by the European Regional Development Fund and the Spanish Government.
Thanks to the success of this collaboration, the first prototype for the analysis of genomic data is already available and it is being used for the analysis of large sample sets. Progress will be presented at the fifth edition of the conference ‘ Clinical Genomics and Informatics ‘ organized by Bio -IT World and Cambridge Healthtech Institute this coming 5-6 December in Lisbon, where Integromics will have an oral presentation within the session ‘ Analytical Tools ‘ and FPGMX in the session ‘Translation into the Clinic’.
More information at:
Victor Canivell, CEO of Integromics, speaks about how the company was created several years ago after a thoughtful analysis of the market potential for bioinformatics solutions. The innovative character of Integromics’ business approach and products has won the company high profile international partners, clients and awards.
Biotechnology is a growing sector of the Spanish economy and a good opportunity for investors that seek important returns. In 2012 the turnover of the biotechnological companies grew 25%. Although biotech and bioinformatics entail certain investment risks, companies like Integromics demonstrate that international success is clearly possible.
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced a strategic alliance with Integromics, S.L., a leading supplier of omics data analysis solutions, to become the sole worldwide distributor of Integromics’ software for the TIBCO Spotfire data visualization platform. In addition, PerkinElmer and Integromics announced the release of OmicsOffice 5.0, developed by Integromics. The new OmicsOffice software will be exclusively available from PerkinElmer under the agreement.
OmicsOffice allows users of TIBCO Spotfire to handle, process, analyze and properly visualize diverse genomics data. The software provides scientists with a rich and flexible set of statistical and functional analysis tools specifically for the study and cross-validation of microarray, next generation sequencing and qPCR data on a single platform, and allows them to extract relevant and reliable biological conclusions from genomic data. Using OmicsOffice, genomics scientists can significantly improve the quality of their results, as they respond to scalability and integration challenges in this rapidly evolving field.
Michael Stapleton, general manager, PerkinElmer Informatics said, “We are delighted that PerkinElmer will take on distribution of the new OmicsOffice product. It represents a true synergy with our mission to offer end-to-end informatics solutions throughout the research, discovery and manufacturing processes. As the exclusive worldwide distributor of OmicsOffice, we can provide focused solutions to the genomics and next generation sequencing community to improve the quality of their work and gain critical insights faster than before.”
“PerkinElmer is the perfect partner for Integromics, particularly for OmicsOffice,” said Víctor Canivell, PhD, Chief Executive Officer of Integromics. “PerkinElmer’s leadership in technologies for scientific discovery and its commitment to advanced analysis tools, provides us with an excellent opportunity to bring the power of OmicsOffice to genomic researchers, as well as to accelerate the release of new omics analysis tools.”
PerkinElmer is a leading provider of discovery, collaboration, and knowledge enterprise solutions, desktop software, scientific databases and consulting services to the pharmaceutical, biotechnology, and chemical industries. The Company offers enterprise solutions, desktop software, scientific databases, and professional services for biotechnology, drug discovery and chemical research, including software, databases, and web sites which enable customers to create, analyze and communicate chemical, biological, and scientific information more effectively. Learn about our informatics solutions at www.perkinelmer.com/informatics.
If you want to learn more about the new OmicsOffice Suite click here and/or contact us.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
INTEGROMICS, S.L. provides IT solutions for life sciences in the areas of genomics and proteomics. Integromics offers state-of-the-art products, services and training for intelligent, visual analysis and integration of biological data. Its international network of collaborators in industry and academia helps researchers to achieve faster and more complete biological interpretations of experimental omics data. Integromics was founded in 2002 in Granada, Spain. Additional information is available at http://www.integromics.com.]]>
Granada and Madrid, Spain and Madison, WI, U.S., April 18, 2013 – Integromics®, a market leader in IT solutions for life sciences in the field of genomics and proteomics, today announces that it has entered into a partnership with the Celgene Institute for Translational Research Europe (CITRE) and the Centre of Studies and Technical Research (CEIT), for the execution of SANSCRIPT, a project that aims at the development of new data analysis methods applied in clinical genomics studies.
Based on the strength of its R&D work, the new partnership has been awarded a EUR two million grant from the Spanish Government for the development of algorithms and statistical tools to identify alternative splicing events significantly related with disease associated biomarkers or therapeutic targets using RNA sequencing (RNA-seq).
Current algorithms, due to their intrinsic characteristics, have major limitations in characterizing gene alterations, which are frequently related to drug resistance and other phenotypes. Therefore, it is essential to adapt the present methods developed for the new massive sequencing technologies to extract all their potential for development of diagnostic and prognostic tests, and drug discovery in the clinical and pharmaceutical environment.
The SANSCRIPT collaboration, coordinated by Integromics, has been designed to address these issues through the synergy between the engineers at CEIT, scientists at CITRE and the bioinformaticians from Integromics, which will undoubtedly accelerate the development of solutions for personalized medicine. The new solutions will be validated for personalized-drug development processes where gene expression is essential to understand the differing responses to treatment.
The SANSCRIPT project represents an ideal opportunity for Integromics to reinforce its commitment to the development of software solutions for personalized medicine in the context of clinical studies. “This is the first time that we can effectively work hand in hand with both an advanced software engineering team from a first class Technical Center and a research group from a leading biopharmaceutical corporation to cooperatively address an important gap”, said Eduardo González Couto, Chief Strategy Officer, Integromics. “The SANSCRIPT grant provides key financial support for us to spearhead the usage of NGS for drug development and help us make personalized medicine a reality.”
“Automated next-gen sequencers have increased the speed and reduced the cost of sequencing, making it possible to offer genetic testing to consumers. Producing the genomic data is not a problem anymore, while the analysis and interpretation of this data has become the ‘new hurdle’ ”, continues Dr. Gonzalez Couto. “In order to identify the gene expression changes associated to sensitivity to treatment, including the detailed characterization of transcription isoforms for clinical usage, bioinformatics tools are crucially needed to design novel algorithms from the very beginning to be compatible with long reads from upcoming NGS technologies.”
“For us it is a pleasure to work with both a leading Spanish biosoftware company and a Pharma industry. This collaboration will help us to focus on a specific problem and provide a solution: algorithms that identify gene aberrations related to drug resistance in cancer” said Prof. Angel Rubio, Principal Investigator of the CEIT. “We are quite excited in working to improve the health: even though we have had other projects related with human health, they were not so ambitious as this one” concluded Prof. Rubio.
As genome sequencing continues to take footholds in diagnosis, prognosis and treatment of diseases, it is expected that the findings of the SANSCRIPT project, in terms of software and new methodologies, will enhance the reliability and significance of the next generation sequencing (NGS) technology in the pipelines of drug development and clinical genomics studies.
The results of SANSCRIPT will be made available through new releases of the Integromics’ OmicsOffice® software suite. This will give clinical drug discovery scientists an immediate access to the fruits of the SANSCRIPT project, allowing them to apply new data analysis methods to their own studies.
Integromics develops and markets advanced data analysis solutions for life sciences in the areas of genomics and proteomics with the goal of accelerating researchers’ time to biological interpretation. Integromics offers state-of-the-art products for intelligent, interactive, visual analysis of big omics data. The company’s OmicsOffice® suite of products is used by hundreds of customers to address the key omics analysis and interpretation bottlenecks. The company has developed a powerful network of partnerships both in industry and academia, having led a number of major national and European public research projects. Integromics headquarters are in Spain.
For more information, visit http://www.integromics.com/
About the Celgene Institute for Translational Research Europe (CITRE)
Celgene Institute for Translational Research Europe (CITRE), based in Seville, Spain, a wholly owned subsidiary of Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
For more information, please visit the company’s Web site at http://www.celgene.com/research/citre_overview.aspx.
About the Centre of Studies and Technical Research (CEIT)
CEIT is a private multidisciplinary non-profit research centre closely connected to TECNUN, the Faculty of Engineering of the University of Navarra (Spain). Its mission is to provide the industry with services through the development of technical research projects and to form young researchers and PhD students. CEIT promotes excellence in applied research by publishing non confidential results and participating in scientific and technical forums. The centre also has a comprehensive doctoral teaching program in the different engineering areas.
CEIT understands all aspects of the client’s position and therefore can seek out the best possible collaborations across the industry. CEIT promotes high added value solutions through research projects and by training young researchers within a commercially productive framework.
For more information, visit http://www.ceit.es/]]>